The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors
Abstract
Although the hallmarks of neurodegeneration in Alzheimer's brains are well known, one of the current difficulties is related to the lack of solid evidence about the ultimate factors that give rise to the pathogenesis of this disease, creating a great challenge for the definition of efficient treatments for Alzheimer's disease (AD). Current therapeutic option for AD patients is the use of acetylcholinesterase (AChE) inhibitors, which gives only a symptomatic relief. However, recent studies show a long-lasting effect in a certain percentage of patients. In fact, there is accumulating evidence that an AChE has secondary non-cholinergic functions including the processing and deposition of beta-amyloid (Abeta). AChE could play a role in the Abeta metabolism and during an early step in the development of the senile plaque, as revealed by the finding that AChE accelerates Abeta deposition. Considering the non-classical AChE functions, their relationships with AD hallmarks, and the putative role of peripheral anionic site in all these functions, the dual binding site AChE inhibitors may acquire importance for AD treatment. On the other hand, the interference of AChE inhibitors with Abeta processing is not a general rule for this class of compounds with the involvement of other features such as chemical structure and/or genetic regulation. This review highlights the collection of several compounds with an outstanding profile against AChE-induced amyloid aggregation and potent AChE inhibitory activity, indicating the possibility of targeting Abeta through the inhibition of AChE and reveals the emergence of a new generation of AChE inhibitors aiming to be excellent candidate drugs for the future cure of Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the conformational changes due to AChE-Aβ complex formation also enhanced the metabolism of Aβ and senile plaque generation [30].”
From Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy (2021) · cites this paper as [30]
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,221
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Jennifer, C., & Dougherty, D. A. (1997) · Chemical Reviews · doi:10.1021/cr9603744 · Cited by 3,518
Acetylcholinesterase — new roles for an old actor
Soreq, H., & Seidman, S. (2001) · Nature reviews. Neuroscience · doi:10.1038/35067589 · Cited by 1,437
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
Inestrosa, N. C., Alvarez, A. R., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C. A., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,117
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies.
Bartolini, M., Bertucci, C., Cavrini, V., & Andrisano, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01514-9 · Cited by 523
Strategies for disease modification in Alzheimer's disease
Citron, M. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1495 · Cited by 430
Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease
Giacobini, E. (2003) · Neurochemical Research · doi:10.1023/a:1022869222652 · Cited by 374
Cited by
Sorted by citations
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Leon, R. M., García, A. G., & Marco, J. L. (2011) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 447
CHOLINESTERASES, A TARGET OF PHARMACOLOGY AND TOXICOLOGY
Pohanka, M. (2011) · Biomedical Papers · doi:10.5507/bp.2011.036 · Cited by 377
Hampel, H. J., Mesulam, M. M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.43 · Cited by 374
Metadata
- Authors
- Castro, A., & Martinez, A.
- ORCID
- Castro, Ana
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-11-01
- Volume
- 12
- Issue
- 33
- Pages
- 4377-4387
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1976042714
- Cited by
- 207
- References
- 75
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 12 · 2023: 7 · 2022: 13 · 2021: 13 · 2020: 12 · 2019: 10 · 2018: 7 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 9 · 2013: 8 · 2012: 15
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- Alzheimer's disease, amyloid-beta, acetylcholinesterase inhibitors, amyloid fibril formation, peripheral anionic site, dual binding site inhibitors, amyloid plaques, amyloid deposition
- MeSH terms
- Alzheimer Disease, Cholinesterase Inhibitors, Humans, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
